XYF ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds X

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
58
XYF ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds X Financial Investors of Important February 7th Deadline in Securities Class Action – XYF

NEW YORK, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of X Financial (NYSE: XYF) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with X Financial’s September 2018 initial public stock offering (the “IPO”) of the important February 7, 2020 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for X Financial investors under the federal securities laws.

To join the X Financial class action, go to http://www.rosenlegal.com/cases-register-1733.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, the Registration Statement featured false and/or misleading statements and/or failed to disclose that: (1) the Company’s total loan facilitation amount was not growing, but rather was contracting; (2) the number of investors actively using X Financial’s platform was shrinking; (3) demand from small- and medium-sized enterprises for the Company’s Xiaoying Preferred Loans (“preferred loans”) was plummeting; (4) the Company’s preferred loans had performed so poorly that it had begun drastically scaling back its preferred loans in the first quarter of 2018, several months before the IPO, and was in the process of phasing out such loans completely; (5) demand for the Company’s Xiaoying Card Loans was also plummeting; (6) the revenue and loan facilitation growth provided in the Registration Statement leading up to the IPO was achieved by relaxed credit and due diligence standards, under which the Company had underwritten tens of millions of dollars’ worth of poor quality loans that suffered from a disproportionately high risk of default as compared to the Company’s earlier loan vintages; (7) the Company was suffering from accelerated delinquency rates from poor quality loans that it had underwritten in the first, second, and third quarters of 2018, which had caused the Company’s delinquency rate to sharply rise; (8) the Company’s product mix had significantly deteriorated; (9) the Company’s net revenue was on track to decline by 22% during the third quarter of 2018; and (10) as a result, defendants’ statements about X Financial’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 7, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1733.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com .

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.       Phillip Kim, Esq.       The Rosen Law Firm, P.A.       275 Madison Avenue, 40 th Floor       New York, NY 10016       Tel: (212) 686-1060       Toll Free: (866) 767-3653       Fax: (212) 202-3827       lrosen@rosenlegal.com       pkim@rosenlegal.com       cases@rosenlegal.com       www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Exro Technologies Reveals Quarterly Progress and Financial Insights

Updated Category News Views 362

Exro Technologies Reports First Quarter Results Exro Technologies Inc. (TSX: EXRO), a prominent tech company specializing in power control solutions for electric vehicles and energy storage, has recently announced its financial results for the first quarter of the year. This highlights their ongoing transition from technology validation towards commercial operations and...

Continue Reading
dsm-firmenich Appoints New Leaders to Propel Future Growth

Updated Category News Views 548

dsm-firmenich Welcomes New Executive Committee Members dsm-firmenich is set to usher in a transformative era by strengthening its Executive Committee, as it embarks on a journey to intensify its consumer-centered approach. This restructuring aims to solidify its standing as a top-tier partner in creation and innovation across the nutrition, health, and beauty sectors. The...

Continue Reading
Insight Partners Rolls Out $12.5B for Software Innovation Growth

Updated Category News Views 805

Insight Partners Launches New Funds to Propel Software Innovation Global software investor, Insight Partners, has recently celebrated a significant milestone by announcing the closing of its thirteenth flagship fund alongside a dedicated buyout co-invest fund, collectively known as "Fund XIII". This announcement is particularly special as it coincides with the firm's 30th...

Continue Reading
Acumatica's AI Innovations Transform Business Operations

Updated Category News Views 123

Acumatica's AI Innovations Transform Business Operations During an inspiring keynote at a recent summit, Acumatica showcased its commitment to revolutionizing business operations with an AI-first product strategy. This innovative approach aims to significantly enhance how small and mid-sized businesses operate, addressing the real-world challenges they face. With advanced...

Continue Reading
Microbiological Testing of Water Market Growth Forecasts

Updated Category News Views 101

The Expanding Microbiological Testing of Water Market As the demand for clean and safe water continues to surge, the global microbiological testing of water market is set to experience significant growth, reaching an impressive $2.3 billion by 2027, with a robust compound annual growth rate (CAGR) of 7.4%. The rising consciousness among consumers regarding the importance...

Continue Reading